AstraZeneca Pharma Share Price Drops 4%; Q4 FY26 Profit Down 23%

AstraZeneca Pharma India announced its financial results for the quarter and financial year ended March 31, 2026. The company reported a decline in quarterly profit amid rising expenses, even as revenue from operations registered year-on-year growth. 

Following the earnings announcement, AstraZeneca Pharma India shares came under pressure and fell more than 4% during morning trade on May 27, 2026. However, the company’s full-year FY26 performance reflected growth in both revenue and profitability.

AstraZeneca Pharma India Q4 FY26 Results

AstraZeneca Pharma India posted a net profit of ₹44.88 crore for the March quarter of FY26, compared to ₹58.25 crore reported during the same quarter last year. This represents a decline of around 23% on a year-on-year basis.

Despite lower profit, the company reported higher revenue during the quarter. Revenue from operations increased to ₹578.61 crore in Q4 FY26 from ₹480.48 crore in the corresponding period of the previous financial year, reflecting growth of over 20%.

Expenses Rise During the Quarter

The company’s total expenses rose significantly during the March quarter. AstraZeneca Pharma India reported expenses of ₹525.34 crore, marking an increase of around 27% compared to the year-ago period.

The rise in operational costs impacted overall profitability during the quarter despite stronger revenue performance.

Full-Year FY26 Performance

For the full financial year ended March 31, 2026, AstraZeneca Pharma India reported a net profit of ₹187.52 crore. This reflects growth of approximately 62% compared to FY25.

The company’s total revenue for FY26 stood at ₹2,275.58 crore, registering an increase of nearly 33% year-on-year.

The annual performance indicates continued growth in the company’s business operations despite pressure on quarterly margins.

AstraZeneca Pharma Share Price Performance

Following the quarterly earnings announcement, AstraZeneca Pharma India shares declined in early trade on May 27, 2026.

At around 9:58 AM, the stock was trading at ₹8,547.50 on the NSE, down 4.63% from the previous close of ₹8,962.50.

Investors appeared to react to the decline in quarterly earnings and the increase in expenses during the reporting period.

Read More: Gold and Silver Price Today in Chennai: 24K at ₹1,58,560/10g, Silver at ₹2,72,740/kg (May 27 Update)

Want to track these market movements in Hindi? Visit Angel One News for daily updates and comprehensive share market news in Hindi.

Conclusion

AstraZeneca Pharma India reported mixed Q4 FY26 results, with revenue growth offset by a decline in profitability due to higher expenses. While the company’s annual earnings and revenue showed improvement, market participants may continue to monitor margin trends, operational performance and future growth developments in the pharmaceutical business.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.